Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir plus vedolizumab versus vedolizumab alone in CMV-positive relapsing ulcerative colitis
2019-001032-54Phase 4Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Jun 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in autoimmune colitis and cytomegalovirus disease (CMV) comparing Vedolizumab + valganciclovir with Vedolizumab without antiviral (2 arms). Primary endpoint: Clinical response at week 6. Started Jun 2019; status: terminated.
02
Drugs
valganciclovirvedolizumab
03
Conditions
autoimmune colitiscytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2019-001032-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001032-54.